BOSTON – December 3, 2021 – Pear Therapeutics, Inc. (“Pear Therapeutics”), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), announced today the completion of its business combination with Thimble Point Acquisition Corp. (“Thimble Point”) (Nasdaq: THMA), a special purpose acquisition company (“SPAC”). The publicly traded company will be known as Pear Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “PEAR” on December 6, 2021.
Thimble Point’s shareholders approved the business combination on November 30, 2021, and the transaction was previously approved by Pear Therapeutics’ shareholders.
My Pearmates and I are proud to continue our leadership in the creation of prescription digital therapeutics, said Corey McCann, M.D., Ph.D., Pear’s President and Chief Executive Officer. As a public company, we aim to accelerate our vision to increase access to PDTs by further commercializing our three FDA-authorized PDTs, expanding public and private payer adoption, and advancing our pipeline of PDTs. Thanks to all of our investors for supporting our successful transition.
Net proceeds from the business combination will be used to further capitalize Pear’s category-leading position as the leader in software to treat serious disease.
The transaction generated approximately $175 million in gross proceeds.
